Vortosiran
Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran is internalized via ASGPR-mediated endocytosis, subsequently regulating mRNA translation to suppress FXI synthesis. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 3061406-99-0
- 화학식: C463H620F7N154O291P39S6
- 분자량:14532.10
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
|
FXI |
ASGPR |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:female C57BL/6J mice[2]
-
Dosage:1, 3 and 9 mg/kg
-
Administration:s.v.; single dose
-
Result:Prevented arterial and venous thrombosis, but tail bleeding did not prolong.
Chemical Information
-
CAS No. 3061406-99-0
-
분자량 14532.10
-
화학식 C463H620F7N154O291P39S6
-
SMILES
[Vortosiran]
-
Synonyms
RBD4059
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Gabrielsen A, et al. RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran). Blood advances. 2026 Apr 14;10(7):2541-2548. [Content Brief]
[3]. Yuan H, et al. Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors. Front Immunol. 2026 Oct 5;17:1925585. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)